Immix sets mid-2027 filing for amyloidosis CAR-T with $340.9m in the bank

Immix Biopharma has told investors it expects to file for US approval of its CAR-T cell therapy NXC-201 in mid-2027. It also reported $340.9m in cash, which it says will last until mid-2028. On those dates, the balance sheet would cover roughly a year after the planned submission. The company gave no revenue figures or commercial projections in the material reviewed.

The update came with third-quarter 2026 results on 12 November. NXC-201 targets BCMA and is being developed for relapsed or refractory AL amyloidosis. Interim results from the NEXICART-2 study showed 89% of 45 patients achieving a complete response. Immix will present the data orally at the American Society of Hematology meeting on 14 December.

The headline figure comes without the detail that usually shapes how such data are read. The information available does not cover follow-up length, safety findings or the response criteria used. Those points will matter when the full dataset is shown, particularly for a therapy that will have to be compared with existing treatments.

Immix has also appointed new heads of technical operations and regulatory affairs. As general context, manufacturing and regulatory readiness tend to become pressing for autologous cell therapies ahead of a licence filing, because each patient's product is made individually. The company did not describe its manufacturing arrangements in the material reviewed.